Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
2 vehicles on file, newest listing first
none appears on more than one · 1 vehicle carry no counterparty filing we have read
Mary T. Szela is a seasoned biopharmaceutical executive and board director who currently serves as Chief Executive Officer and President of TriSalus Life Sciences, Inc., a position she has held since January 2018. TriSalus is an immuno-oncology company developing therapeutics and disruptive delivery technologies to administer immune oncology agents to solid tumors in high-mortality cancers, particularly liver and pancreatic tumors. In addition to her executive role, Szela serves as a director on the board of Averin Capital Acquisition Corp. (Nasdaq: ACAAU), a $250 million special purpose acquisition company that priced its IPO in February 2026 under the leadership of Chairman and CEO Dr. David A. Berry. Averin Capital is focused on identifying and merging with a private company at the intersection of technology and healthcare, targeting areas such as AI-driven diagnostics, digital therapeutics, and personalized medicine. Szela's appointment to the Averin board alongside industry veterans Ulrik Schulze and Graeme Bell brings deep commercial pharmaceutical and public-market governance experience to the SPAC's deal evaluation and strategy oversight.
Szela's career spans nearly 35 years in the biotechnology and pharmaceutical industries. She began at Abbott Laboratories in 1987, where she spent 25 years in ascending management positions, including 14 years in leadership roles within the pharmaceutical division culminating as President of the company's $8 billion U.S. pharmaceutical business. During her Abbott tenure, she developed multi-billion-dollar brands and led the world's largest-selling pharmaceutical product, Humira, through the launch of nine indications. After leaving Abbott, she served as CEO of Melinta Therapeutics, where she led the company's revitalization effort and accelerated clinical development of its lead asset and pipeline. She subsequently became CEO of Novelion Therapeutics, where she resolved significant legal, regulatory, and compliance issues and executed a merger of Aegerion Pharmaceuticals and QLT Therapeutics to re-capitalize the company within her first year. Earlier, she had been named CEO of Aegerion Pharmaceuticals in January 2016, succeeding interim CEO Sandford "Sandy" Smith after the controversial departure of Marc Beer, and she was tasked with stabilizing the rare-disease drug company and repositioning its orphan drugs Juxtapid and Myalept amid new PCSK9 competition. She later stepped down as CEO of Melinta in September 2015 before taking the Aegerion role.
Szela's board portfolio is extensive and reflects her expertise in global brand development, commercial strategy, and mergers and acquisitions. She has served on the boards of publicly held companies including Receptos Inc., which was acquired by Celgene for $7.2 billion in July 2015; Novo Nordisk; and Novelion Therapeutics. She currently serves or has served on the boards of Coherus Biosciences, Kura Oncology, Alimera Sciences, TriSalus Life Sciences, Omega Therapeutics, Absci, and Kintai Therapeutics, a Flagship Pioneering company where she was appointed in July 2019. She has also advised chief executives and executive teams on strategy, growth, and mergers. Szela earned a B.S. in Nursing and an M.B.A. from the University of Illinois at Chicago. She is based in Deerfield, Illinois, and is recognized as a prominent voice in the life sciences community, having spoken at industry events such as the Smart Business Dealmakers conference in Denver. Her track record of advancing transformative therapies, executing complex corporate transactions, and guiding companies from clinical development through commercialization positions her as a valuable strategic asset to both TriSalus and the Averin Capital SPAC as it pursues a high-value health-technology merger.
This record is keyed to SEC CIK 0001410289 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 71 institutional-holder rows on these vehicles, under 33 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.